IL138022A0 - High affinity humanized anti-cea monoclonal antibodies - Google Patents

High affinity humanized anti-cea monoclonal antibodies

Info

Publication number
IL138022A0
IL138022A0 IL13802298A IL13802298A IL138022A0 IL 138022 A0 IL138022 A0 IL 138022A0 IL 13802298 A IL13802298 A IL 13802298A IL 13802298 A IL13802298 A IL 13802298A IL 138022 A0 IL138022 A0 IL 138022A0
Authority
IL
Israel
Prior art keywords
monoclonal antibodies
high affinity
humanized anti
cea monoclonal
affinity humanized
Prior art date
Application number
IL13802298A
Other languages
English (en)
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Publication of IL138022A0 publication Critical patent/IL138022A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007Carcino-embryonic Antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853Carcino-embryonic antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1048Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57565Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen [CEA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13802298A 1998-02-25 1998-02-25 High affinity humanized anti-cea monoclonal antibodies IL138022A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/003680 WO1999043817A1 (fr) 1998-02-25 1998-02-25 Anticorps monoclonaux anti-ace humanises et faisant preuve d'une grande affinite

Publications (1)

Publication Number Publication Date
IL138022A0 true IL138022A0 (en) 2001-10-31

Family

ID=22266464

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13802298A IL138022A0 (en) 1998-02-25 1998-02-25 High affinity humanized anti-cea monoclonal antibodies

Country Status (7)

Country Link
EP (1) EP1056859A1 (fr)
JP (1) JP2002504372A (fr)
AU (1) AU752494B2 (fr)
CA (1) CA2321947A1 (fr)
IL (1) IL138022A0 (fr)
NO (1) NO20004251L (fr)
WO (1) WO1999043817A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003025565A2 (fr) * 2001-09-21 2003-03-27 Caprion Pharmaceuticals Inc. Preparation de membranes plasmiques fortement purifiees
CA2609142C (fr) 2005-05-27 2016-02-09 Fondazione Centro San Raffaele Del Monte Tabor Vecteurs geniques therapeutiques comprenant des sequences cibles de microarn
PE20141017A1 (es) * 2011-03-02 2014-08-25 Roche Glycart Ag Anticuerpos del cea
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CN111533805B (zh) * 2016-12-04 2022-02-08 深圳市国创纳米抗体技术有限公司 一种抗癌胚抗原的高亲和力纳米抗体及其应用
CN113906053B (zh) 2019-06-26 2022-10-25 江苏恒瑞医药股份有限公司 抗cea抗体及其应用
CA3188867A1 (fr) 2020-08-20 2022-02-24 Xueyin Wang Compositions et methodes de traitement de cancers positifs a ceacam
IL300500A (en) 2020-08-20 2023-04-01 A2 Biotherapeutics Inc Preparations and methods for the treatment of mesothelin positive cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5472693A (en) * 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
AU719513B2 (en) * 1996-05-04 2000-05-11 Astrazeneca Ab Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system

Also Published As

Publication number Publication date
WO1999043817A1 (fr) 1999-09-02
NO20004251L (no) 2000-10-24
AU6338898A (en) 1999-09-15
CA2321947A1 (fr) 1999-09-02
EP1056859A1 (fr) 2000-12-06
NO20004251D0 (no) 2000-08-24
AU752494B2 (en) 2002-09-19
JP2002504372A (ja) 2002-02-12

Similar Documents

Publication Publication Date Title
IL128406A0 (en) Monoclonal antibodies
PL311926A1 (en) Anti-alphav-integrinic monoclonal antibodies
EP1073464A4 (fr) Anticorps monoclonaux presentant une immunogenicite reduite
IL115232A0 (en) Monoclonal antibodies against colon carcinoma-associated antigens
AU1462300A (en) Human pan-hcv human monoclonal antibodies
DK1516629T3 (da) Humaniseret anti-CD-11a antibodies
AU2559799A (en) Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
AU1687500A (en) Antihuman vegf monoclonal antibody
IL147517A0 (en) Monoclonal antibodies and immunoassay utilizing the same
AU6702998A (en) Anti-alphabeta3 humanized monoclonal antibodies
AU4441799A (en) Monoclonal antibodies that recognize antigens associated with tumor metastasis
HUP0103573A3 (en) Antithrombotic agent and humanized anti-von willebrand factor monoclonal antibody
GB9608626D0 (en) Hepatitis b monoclonal antibodies
AU7072998A (en) Immunoassays using anti-allotypic monoclonal antibodies
EP0578515A3 (fr) Anticorps monoclonaux humanisés.
IL138022A0 (en) High affinity humanized anti-cea monoclonal antibodies
GB9718911D0 (en) Monoclonal antibodies
AU2596397A (en) Monoclonal antibody that detects apoptotic antigen
ZA951113B (en) Tumor assosiated monoclonal antibody 123av16
GB9721432D0 (en) Improved production of antibodies through the use of antigen antibody complexes
EP1106701A4 (fr) Anticorps monoclonal agissant contre la trypsine canine
AP9801381A0 (en) Anti-human mp52 monoclonal antibody
EP0654532A4 (fr) Anticorps monoclonal antimucoglycoproteine.
GB9615027D0 (en) Monoclonal antibodies
AU7320998A (en) CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies